07 Dec 2025
7m
ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.